Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

NCT ID: NCT00361153

Last Updated: 2008-06-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 35 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-05-31
• Study Completion Date: 2007-03-31

Brief Summary

This study is designed to test whether WelChol (colesevelam HC1) improves blood sugar control in patients with type 2 diabetes by making their own insulin work more efficiently.

Detailed Description

Single-center, randomized, parallel, double-blind, placebo controlled, 8-week trial in subjects with type 2 diabetes mellitus. Two parallel treatment groups include double-blind colesevelam or placebo. A screening period may be up to 18 weeks to withdraw non sulfonylurea antidiabetic treatment or withdraw or adjust sulfonylurea antidiabetic treatment. To evaluate hepatic and peripheral insulin sensitivity, subjects will undergo a two-step hyperinsulinemic-euglycemic clamp with a tritiated glucose infusion at pre randomization and after 8 weeks of treatment. To evaluate oral glucose absorption, subjects will undergo two oral glucose tolerance tests (OGTT) at pre randomization, one without colesevelam and one with colesevelam, and one OGTT at the end of the treatment period..

Conditions

Type 2 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

1

Colesevelam hydrochloride

Group Type: ACTIVE_COMPARATOR

Colesevelam hydrochloride

Intervention Type: DRUG

Welchol tablet 625mg

2

placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

placebo

Interventions

Colesevelam hydrochloride

Welchol tablet 625mg

Intervention Type: DRUG

placebo

placebo

Intervention Type: DRUG

Other Intervention Names

Welchol

Eligibility Criteria

Inclusion Criteria

Subjects meeting the following criteria at the Screening Visit will be eligible to participate in the trial:

• Have given written informed consent
• Ages 18 to 75 years, inclusive
• Diagnosis of type 2 diabetes mellitus of at least 3 months duration
• HbA1C 7.0- 10.0%, inclusive
• Antidiabetic treatment may include oral agents; all antidiabetic agents must be withdrawn before randomization
• Women may be enrolled if they are not pregnant (negative serum βHCG at the Screening Visit), are not breast-feeding, and do not plan to become pregnant during the trial. In addition, they must either have had a hysterectomy or tubal ligation at least 6 months before signing informed consent, be post-menopausal for 1 year, or practicing an acceptable method of birth control. An acceptable method of birth control may be oral, injectable or implantable hormonal contraceptives, intrauterine device, diaphragm plus spermicide, or female condom plus spermicide. Abstinence, partner's use of condoms, and partner's vasectomy are NOT acceptable methods of contraception
• BMI 25 - 45 kg/M sq, inclusive

Exclusion Criteria

Subjects are excluded from participation in the study if any of the following criteria apply:

• Type 1 diabetes mellitus or history of diabetic ketoacidosis
• Treatment with lipid or blood pressure lowering therapy that has not been stable for three months before randomization
• Treatment with WelChol, cholestyramine or colestipol for hyperlipidemia within the last 3 months
• Treatment with thiazolidinediones
• History of dysphagia, swallowing disorders, or intestinal motility disorder
• Serum triglyceride >500 mg/dL at Visit 1
• Serum LDL-C <60 mg/dL at Visit 1
• Any condition or therapy which, in the opinion of the investigator, poses a risk to the subject or makes participation not in the subject's best interest
• Use of any investigational drug within 30 days before randomization
• Chronic treatment with oral corticosteroids
• History of hyperthyroidism and/or treatment with thyroid hormone/ levothyroxine

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Daiichi Sankyo

INDUSTRY

Sponsor Role: lead

Responsible Party

Daiichi Sankyo

Principal Investigators

Director Clinical Development

Role: STUDY_DIRECTOR

Daiichi Sankyo

Locations

Diabetes and Glandular Research Associates

San Antonio, Texas, United States

Countries

United States

References

Schwartz SL, Lai YL, Xu J, Abby SL, Misir S, Jones MR, Nagendran S. The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot study. Metab Syndr Relat Disord. 2010 Apr;8(2):179-88. doi: 10.1089/met.2009.0049.

Reference Type: DERIVED

PMID: 20059361 (View on PubMed)

Other Identifiers

WEL-202

Identifier Type: -

Identifier Source: org_study_id